Motohashi Kenji, Ito Satomi, Hagihara Maki, Sakai Rika, Tanaka Masatsugu, Kawano Tomoko, Maruta Atsuo, Ishigatsubo Yoshiaki, Kanamori Heiwa
Department of Hematology, Kanagawa Cancer Center, Japan.
Rinsho Ketsueki. 2009 May;50(5):430-4.
We report five patients with acute leukemia who underwent allogeneic hematopoietic stem cell transplantation (HSCT) following surgical resection of pulmonary aspergillosis. The patients were three men and two women with a median age of 40 (range, 32 approximately 60). The diagnosis, based on CT imaging, Aspergillus antigen, culture, and histopathology of resected lung specimens, included two proven and three possible pulmonary aspergillosis. Median duration from surgery to HSCT was 2.5 months (range, 1.0 approximately 20). Pre-transplant restrictive-type lung dysfunction was observed in four patients. Antifungal prophylaxis after HSCT was attempted with voriconazole in three patients, amphotericin-B in one patient, and micafungin in one patient. No patients experienced a relapse of pulmonary aspergillosis, although three patients died after HSCT. The causes of death included leukemia relapse in two and hemophagocytic syndrome in one. These results suggest that pre-transplant surgical resection with post-transplant prophylactic antifungal agents seems to be an effective strategy to prevent the relapse of pulmonary aspergillosis in patients with residual disease in the lung before allogeneic HSCT.
我们报告了5例急性白血病患者,他们在接受肺曲霉菌病手术切除后进行了异基因造血干细胞移植(HSCT)。患者为3名男性和2名女性,中位年龄40岁(范围32至60岁)。根据CT成像、曲霉菌抗原、培养及切除肺标本的组织病理学检查,诊断包括2例确诊和3例可能的肺曲霉菌病。手术至HSCT的中位时间为2.5个月(范围1.0至20个月)。4例患者在移植前出现限制性肺功能障碍。3例患者在HSCT后尝试使用伏立康唑进行抗真菌预防,1例使用两性霉素B,1例使用米卡芬净。尽管3例患者在HSCT后死亡,但无患者发生肺曲霉菌病复发。死亡原因包括2例白血病复发和1例噬血细胞综合征。这些结果表明,移植前手术切除并联合移植后预防性抗真菌药物似乎是预防异基因HSCT前肺部残留疾病患者肺曲霉菌病复发的有效策略。